Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives

6 Feb 2018

Abstract excerpt

Inhibition of DYRK1A kinase, produced by chromosome 21 and consequently overproduced in trisomy 21 subjects, has been suggested as a therapeutic approach to treating the cognitive deficiencies observed in Down syndrome (DS). We now report the synthesis and potent DYRK1A inhibitory activities of fluoro derivatives of 3,5-di(polyhydroxyaryl)-7-azaindoles (F-DANDYs). One of these compounds...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Down syndrome and intellectual disability research
Share to Family and Disability Support Research
Share to Genomic variations and chromosomal abnormalities

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29434250
DOI: 10.1038/s41598-018-20984-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivativesPMID 29434250Read ↗

Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down SyndromeSemantic proximity Read ↗

Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerationsSemantic proximity Read ↗

Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s?Semantic proximity Read ↗

DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down SyndromeSemantic proximity Read ↗

DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down SyndromeSemantic proximity Read ↗

Epigallocatechin‐3‐gallate, a DYRK1A inhibitor, rescues cognitive deficits in <scp>D</scp>own syndrome mouse models and in humansSemantic proximity Read ↗

Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1aSemantic proximity Read ↗

DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicitySemantic proximity Read ↗

Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes.Semantic proximity Read ↗

LONG-TERM NEURODEVELOPMENTAL AND COGNITIVE OUTCOMES FOLLOWING PRENATAL INHIBITION OF DYRK1A BY LEUCETTINE L41 IN MOUSE MODELS OF DOWN SYNDROMESemantic proximity Read ↗

A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.Semantic proximity Read ↗

New Perspectives for the Rescue of Cognitive Disability in Down SyndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.